The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Reflecting the sensitivity of biotech stocks to insurance coverage progress, ARS Pharmaceuticals announced no new coverage decisions for its Neffy epinephrine nasal spray in the July formulary cycle, causing the stock to drop after hours. The commercial update disappointed investors who had hoped for progress in securing coverage that is critical for the product's commercial success.
The announcement comes months after Neffy received FDA approval, according to reports, yet insurance coverage decisions remain pending. The stock closed at $10.28 on June 23 (the last session before the announcement), with no significant pre-close moves in available data. Analysts view the lack of coverage as a key hurdle to Neffy's commercial adoption.
Sign in to access this content
Sign InAt the June 23 close, SPRY shares traded at $10.28, with a daily range of $9.90–$10.45 per market data. Investors will watch upcoming formulary cycles for potential coverage decisions, alongside any regulatory updates or commercial partnerships that could improve the product's outlook.